

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Kelderman Kim</u>  (Last) (First) (Middle) 614 MCKINLEY PLACE NE  (Street) MINNEAPOLIS MN 55413  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [ TECH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner Officer (give title below) Other (specify below)  Pres. Diagnostics & Genom
	3. Date of Earliest Transaction (Month/Day/Year) 08/24/2023	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/24/2023		M		2,100	A	\$47.6	21,225	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option (Right to Buy)	\$37.7							(1)	05/01/2025	Common Stock		27,392	D	
Stock Option (Right to Buy)	\$44.33							(1)	08/08/2025	Common Stock		84,308	D	
Stock Option (Right to Buy)	\$47.6	08/24/2023		M		2,100		(1)	08/07/2026	Common Stock	\$0	109,536	D	
Stock Option (Right to Buy)	\$66.97							(1)	08/05/2027	Common Stock		69,294	D	
Stock Option (Right to Buy)	\$66.97							(3)	08/05/2027	Common Stock		47,952	D	
Restricted Stock Units	(2)							(4)	(4)	Common Stock		4,980	D	
Stock Option (Right to Buy)	\$120.46							(4)	08/06/2028	Common Stock		19,456	D	
Stock Option (Right to Buy)	\$120.46							(5)	08/06/2028	Common stock		25,944	D	
Restricted Stock Units	(2)							(6)	(6)	Common Stock		6,984	D	
Stock Options (Right to Buy)	\$94.52							(6)	08/15/2029	Common Stock		21,704	D	
Stock Options (Right to Buy)	\$94.52							(7)	08/15/2029	Common Stock		28,940	D	
Restricted Stock Units	(2)							(8)	(8)	Common Stock		8,191	D	
Stock Options (Right to Buy)	\$84.61							(8)	08/15/2030	Common Stock		22,043	D	
Stock Options (Right to Buy)	\$84.61							(9)	08/15/2030	Common Stock		29,391	D	

**Explanation of Responses:**

1. Fully exercisable.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
3. Options to purchase 11,988 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.
4. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 12,972 shares are vested. Options to purchase 6,488 shares vest on 8/6/2024 and options to purchase 6,484 shares vest on 8/6/2025.
6. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025.
8. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
9. Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.

/s/ Andrew Nick, Attorney-in-Fact  
for Kim Kelderman pursuant to  
Power of Attorney previously  
filed.      08/28/2023

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**